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SUPPLEMENT ARTICLE CURRENTOPINION First European consensus for diagnosis,
management, and treatment of transthyretin
familial amyloid polyneuropathy Copyright 
www.co-neurology.coma b c d e,fDavid Adams , Ole B. Suhr , Ernst Hund , Laura Obici , Ivailo Tournev ,
Josep M. Campistol g, Michel S. Slamah, Bouke P. Hazenbergi,
Teresa Coelho j, from the European Network for TTR-FAP (ATTReuNET)Purpose of review
Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of
the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy.
There is little consensus in diagnostic and management approaches across Europe.
Recent findings
The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic
expression of the disease means that recognizing symptoms can be difficult outside of a specialized
diagnostic environment. The resulting delay in diagnosis and the possibility of misdiagnosis can misguide
clinical decision-making and negatively impact subsequent treatment approaches and outcomes.
Summary
This review summarizes the findings from two meetings of the European Network for TTR-FAP (ATTReuNET).
This is an emerging group comprising representatives from 10 European countries with expertise in the
diagnosis and management of TTR-FAP, including nine National Reference Centres. The current review
presents management strategies and a consensus on the gold standard for diagnosis of TTR-FAP as well as
a structured approach to ongoing multidisciplinary care for the patient. Greater communication, not just
between members of an individual patient’s treatment team, but also between regional and national centres
of expertise, is the key to the effective management of TTR-FAP.
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Transthyretin familial amyloid polyneuropathy
(TTR-FAP) is a highly debilitating and irreversible
neurological disorder presenting symptoms of pro-





,3]. TTR-FAP is caused by misfolding of the
transthyretin (TTR) protein leading to protein aggre-
gation and the formation of amyloid fibrils and,
ultimately, to amyloidosis (commonly in the per-
ipheral and autonomic nervous system and the
heart) [4,5]. TTR-FAP usually proves fatal within
7–12 years from the onset of symptoms, most often




The prevalence and disease presentation of TTR-
FAP vary widely within Europe. In endemic regions
(northern Portugal, Sweden, Cyprus, and Majorca),
patients tend to present with a distinct genotype in
large concentrations, predominantly a Val30Met© 2016 Wolters Kluwer Health, Inc. All rights reserved.
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KEY POINTS
 TTR-FAP is widely underdiagnosed within Europe, with
misdiagnosis representing one of the most significant
barriers to the timely and effective treatment of patients.
 A pan-European networking of physicians and
pathology laboratories, and the sharing of expertise
and best practice, is the key to optimizing the
diagnostic process.
 Recent pharmacological advances have broadened the
treatment approach to TTR-FAP. The most effective
management plans will take into account the symptoms
and disease characteristics of the individual patient.
 Regular monitoring of the patient by a multidisciplinary
team will track disease progression and allow for
adjustment of the treatment strategy, as necessary.
First European consensus Adams et al.substitution in the TTR gene [8–10]. In other areas
of Europe, the genetic footprint of TTR-FAP is more
varied, with less typical phenotypic expression
[6,11]. For these sporadic or scattered cases, a
lack of awareness among physicians of variable
clinical features and limited access to diagnostic
tools (i.e., pathological studies and genetic screen-
ing) can contribute to high rates of misdiagnosis
and poorer patient outcomes [1
&
,11]. In general,
early and late-onset variants of TTR-FAP, found
within endemic and nonendemic regions, present




Delay in the time to diagnosis is amajor obstacle
to the optimal management of TTR-FAP. With the
exception of those with a clearly diagnosed familial
history of FAP, patients still invariably wait several
years between the emergence of first clinical signs
and accurate diagnosis [6,11,14]. The timely
initiation of appropriate treatment is particularly
pertinent, given the rapidity and irreversibility with
which TTR-FAP can progress if left unchecked, as
well as the limited effectiveness of available treat-
ments during the later stages of the disease [14]. This
review aims to consolidate the existing literature
and present an update of the best practices in the
management of TTR-FAP in Europe. A summary of
the methods used to achieve a TTR-FAP diagnosis is
presented, as well as a review of available treatments
and recommendations for treatment according to
disease status.METHODOLOGY
This article is based on outcomes from two round-
table meetings of the European Network for TTR-
FAP (ATTReuNET) (November 2012 and March Copyright © 2016 Wolters Kluwe
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights rese2014) and a comprehensive review of the published
literature. The group comprised 14 TTR-FAP experts
from 10 European countries (Bulgaria, Cyprus,
France, Germany, Italy, the Netherlands, Portugal,
Spain, Sweden, and Turkey; Tables S1 and S2, http://
links.lww.com/CONR/A39), and includes nine
National Reference Centres (NRCs). The experts
completed a semistructured questionnaire on the
local practice of TTR-FAP disease management in
preparation for bothmeetings (Table S3, http://links.
lww.com/CONR/A39).Groupmembers are clinicians
from a variety of specialties, including neurology,
internal medicine, cardiology, and nephrology.
Electronic database searches (NCBI PubMed)
formed the basis of the literature search within
the time frame (1952 to December 2014). Key search
terms included ‘transthyretin familial amyloid pol-
yneuropathy’, ‘familial amyloid polyneuropathy’,
‘transthyretin amyloidosis’, ‘TTR-FAP’, ‘TTR-FAP
and Europe’, and ‘TTR-FAP and Bulgaria/Cyprus/
France/Germany/Italy/the Netherlands/Portugal/
Spain/Sweden/Turkey’.Misdiagnosis of transthyretin familial
amyloid polyneuropathy
The diagnosis of TTR-FAP presents a significant
challenge to the physician. Given its rarity within
the general population, there is a reduced likelihood
of the evaluating physician immediately recogniz-
ing the symptoms of TTR-FAP without first mistak-
ing them for a more widely seen disorder. Common
misdiagnoses made prior to correctly diagnosing
TTR-FAP include idiopathic axonal polyneuropathy,
chronic inflammatory demyelinating polyneuro-





or chronic alcoholismmay induce polyneuropathies
similar to TTR-FAP [10]. Further potential misdiag-
noses include Charcot–Marie–Tooth neuropathy or
motor neuron disease [1
&
].
The commonly held misconception that TTR-
FAP is a disease of young people with an established
family history and a classic presentation means that
patients exhibiting classic neurological symptoms
without, or with an unknown, familial history may
be overlooked or misdiagnosed [1
&
]. It is often the
case that patients presentingwith inconsistent auto-




The diagnostic process is driven by two compo-
nents. The first is clinical suspicion, which permits
a tentative diagnosis of TTR-FAP through patient
history and physical examination (symptoms andr Health, Inc. All rights reserved.
rved. www.co-neurology.com S15
Consensus for transthyretin amyloid neuropathysigns); the second is diagnostic confirmation using
accurate diagnostic tools, including histopathology







Following a clinical suspicion, positive results from
both biopsy and genetic analysis are essential to






TTR-FAP, and specify the genetic variant [19].
Clinical diagnosis
Patients with TTR-FAP can present with a range of
symptoms [11], and care should be taken to acquire
a thorough clinical history of the patient as well as a
family history of genetic disease. Delay in diagnosis
is most pronounced in areas where TTR-FAP is not
endemic or when there is no positive family history
[1
&
]. TTR-FAP and TTR-familial amyloid cardiomy-
opathy (TTR-FAC) are the two prototypic clinical
diseasemanifestations of a broader disease spectrum
caused by an underlying hereditary ATTR amyloi-
dosis [19]. In TTR-FAP, the disease manifestation of
neuropathy is most prominent and definitive for
diagnosis, whereas cardiomyopathy often suggests
TTR-FAC. However, this distinction is often super-
ficial because cardiomyopathy, autonomic neuro-
pathy, vitreous opacities, kidney disease, and
meningeal involvement all may be present with
varying severity for each patient with TTR-FAP.
Among early onset TTR-FAP with usually
positive family history, symptoms of polyneurop-
athy present early in the disease process and usually
predominate throughout the progression of the dis-
ease, making neurological testing an important
diagnostic aid [14]. Careful clinical examination
(e.g., electromyography with nerve conduction
studies and sympathetic skin response, quantitative
sensation test, quantitative autonomic test) can be
used to detect, characterize, and scale the severity of
neuropathic abnormalities involving small and
large nerve fibres [10]. Although a patient cannot
be diagnosed definitively with TTR-FAP on the basis
of clinical presentation alone, symptoms suggesting
the early signs of peripheral neuropathy, autonomic
dysfunction, and cardiac conduction disorders or
infiltrative cardiomyopathy are all indicators that
further TTR-FAP diagnostic investigation is war-
ranted. Late-onset TTR-FAP often presents as spora-
dic cases with distinct clinical features (e.g., milder
autonomic dysfunction) and can be more difficult







The aim of histopathological analysis is to obtain
direct evidence for amyloid deposits through biopsy
on several possible tissue sites, including the labial Copyright © 2016 Wolters Kluwer 
S16 www.co-neurology.comsalivary gland, abdominal subcutaneous adipose
tissue, gastrointestinal tract, nerve tissue, and other
organs with evidence of involvement (e.g., heart,







is Congo red-stained in order to visualize the extra-
cellular amyloid deposits by their characteristic
apple-green birefringence after crosspolarized light
examination [26,27]. Following biopsy, immuno-
histochemistry can be used to confirm that amyloid
is formed by TTR.
Abdominal fat tissue biopsy and rectal biopsy
are the most frequently performed according to the
members of ATTReuNET, followed by sural nerve
and labial salivary gland biopsy (Table 3). The selec-
tion of biopsy site varies widely between treatment
centres and is largely dependent on the expertise of a
particular team, whereas access to these facilities
depends on the geographical area in which the
patient resides. For example, biopsy sensitivity
depends on the protocol for Congo red staining,
the experience of the pathologist in reading the
slides, and the variable sensitivity, as well as the
specificity of the antibodies used for standard
immunohistochemistry (Table 1) [1
&
,10]. Therefore,
the characterization of amyloid deposits should
preferably be performed by experienced pathol-
ogists in order to minimize the risk of misdiag-
nosis [16
&
,25,28,29]. Conducting repeat biopsy at
different sites to confirm diagnosis is not uncom-
mon (Table 3) (Adams, personal communication,
2014).
Genetic analysis
Genetic testing is carried out to allow detection of
specific amyloidogenic TTR mutations (Table 1),
using varied techniques depending on the exper-
tise and facilities available in each country
(Table S2, http://links.lww.com/CONR/A39). A tar-
geted approach to detect a specific mutation can be
used for cases belonging to families with previous
diagnosis. In index cases of either endemic and
nonendemic regions that do not have a family
history of disease, are difficult to confirm, and have
atypical symptoms, TTR gene sequencing is required
for the detection of both predicted and new amy-
loidogenic mutations [26,27].Postdiagnostic investigations
Following diagnosis, the neuropathy stage and
systemic extension of the disease should be deter-
mined in order to guide the next course of treat-
ment (Table 4) [3,30,31]. The three stages of
TTR-FAP severity are graded according to a
patient’s walking disability and degree of assistance
required [30]. Systemic assessment, especially ofHealth, Inc. All rights reserved.
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Table 2. ATTReuNET-recommended diagnosis of
nonendemic (usually late-onset) TTR-FAP: Key points of note
Typical clinical features of later disease (average 4 years
post onset; the usual delay for diagnosis)
Progressive idiopathic polyneuropathy
Early walking difficulties, using aid support
Initial complaint: [20]
Sensory-motor neuropathic symptoms (80%)
Autonomic symptoms (10%)
Examination: All modality sensory deficit
Presence of family history (less than 50%)
Autonomic neuropathy without diabetes (uncommon at the onset)
Neurogenic orthostatic hypotension
Digestive symptoms (e.g., diarrhoea, constipation)
Urogenital symptoms (e.g., erectile dysfunction)
Unintentional major weight loss
Associated cardiac symptomatology (syncope, dyspnoea)
Diagnosis
DNA testing for TTR mutation (sequencing) first line in the future
Tissue biopsy confirms amyloid deposition
ATTReuNET, European Network for TTR-FAP; TTR, transthyretin; TTR-FAP,
transthyretin familial amyloid polyneuropathy.
Consensus for transthyretin amyloid neuropathythe heart, eyes, and kidney, is also essential to
ensure all aspects of potential impact of the disease
can be detected [10].
The goals of cardiac investigations are to detect
serious conduction disorders with the risk of sudden
death and infiltrative cardiomyopathy. Electrocar-
diograms (ECG), Holter-ECG, and intracardiac
electrophysiology study are helpful to detect con-
duction disorders. Echocardiograms, cardiac mag-
netic resonance imaging, scintigraphy with bone
tracers, and biomarkers (e.g., brain natriuretic pep-
tide, troponin) can all help to diagnose infiltrative
cardiomyopathy [10]. An early detection of cardiac
abnormalities has obvious benefits to the patient,
given that the prophylactic implantation of pace-
makers was found to prevent 25% of major cardiac
events in TTR-FAP patients followed up over an
average of 4 years [32
&&
]. Assessment of cardiac
denervation with 123-iodine meta-iodobenzylgua-
nidine is a powerful prognostic marker in patients
diagnosed with FAP [33].
Eyes
Ophthalmological assessment is warranted to
identify any ocular manifestations of TTR-FAP pre-
senting as keratoconjunctivitis sicca, secondary
glaucoma, vitreous opacities, or pupillary abnormal-
ities [34]. Copyright © 2016 Wolters Kluwer 
S18 www.co-neurology.comKidney
It is also recommended that the monitoring of
proteinuria and renal function form part of the
TTR-FAP diagnostic approach. Microalbuminuria
was detected in 75% of Portuguese patients with
the Val30Met TTR mutation at different timepoints
of the disease, with 21% eventually progressing to
renal failure [35]. Following the onset of neuro-
pathy, dialysis is generally required within 10 years
[36].Recommendations for the diagnosis of
transthyretin familial amyloid polyneuropathy
The current members of ATTReuNET acknowledge
that the existing diagnostic approach taken for TTR-
FAP is suboptimal. Questionnaire data show that
most patients tend to see between three and four
physicians before they receive an accurate diagnosis,
and that a gap of 2–3 years between the emergence
of first symptoms and an accurate diagnosis is not
uncommon [11].
The group calls for a pooling of expertise across
Europe, specifically in relation to diagnosis, by
standardizing techniques and methods in patho-
logical laboratories and facilitating access to TTR
gene testing by providing referral channels to
laboratories with the capacity to confirm diagnosis
of amyloid disease. A gold standard process for TTR-
FAP diagnosis requires clinical, pathological and
genetic evidence in networks under the banner of
NRCs. These are the first steps towards providing
greater urgency to, and improving the quality of,
TTR-FAP diagnosis.
Accurate diagnosis of sporadic cases of TTR-FAP
presents a significant challenge, andspecial attention
should be given to patients presenting with progres-
sive, length-dependent axonal polyneuropathy
predominantly affecting temperature and pain sen-
sation (Table 2). Particular attention should also be
given topatientswith autonomicdysfunction, invol-
untary major weight loss, carpal tunnel syndrome,
and associated cardiac involvement [10,26].Disease management strategies for
transthyretin familial amyloid polyneuropathy
The management of TTR-FAP has expanded signifi-
cantly in recent years; with the availability of phar-
macotherapeutic alternatives, liver transplantation
is no longer the only treatment option [26]. A com-
prehensive care package and a multidisciplinary
approach are required to manage this multisystem
disease. Targeted therapy is essential in the first
instance to prevent further production of amyloid
deposits. Thereafter, symptomatic therapy ofHealth, Inc. All rights reserved.
Volume 29  Supplement 1  February 2016
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s resesensorimotor and autonomic polyneuropathy and
cardiac, renal, and ocular injury is required [6,10].
Finally, genetic counselling to patients and relatives
is recommended [37].
Liver transplant
Prior to the pharmacotherapy era and as early as
1990, orthotopic liver transplant was the standard
of care for patients with TTR-FAP [10,26,38]. A
20-year analysis of survival data from the Familial
Amyloidotic Polyneuropathy World Transplant
Registry of 2044 liver transplant patients reported
a 20-year survival rate of 55.3% after treatment.
Multivariate analysis revealed modified body mass
index, onset of disease (<50 years of age), disease
duration before liver transplant, and TTR
mutation type (Val30Met vs non-Val30Met) as
independent and significant factors for better
survival outcomes (i.e., patients with an early
onset, Val30Met mutation and shorter duration
of the disease have improved prognosis) [39
&&
].
In addition, a large cohort study of 215 consecu-
tive patients who were followed up for 18 years at
the French NRC identified five pejorative factors
for survival after liver transplant: polyneuropathy
disability score score not less than III, orthostatic
hypotension, New York Heart Association (NYHA)
functional class more than I, QRS complex
duration at least 120 ms and thickened interven-
tricular septum [40]. Risks can be computed using
the online calculator by the French Referral Center
for FAP and Other Rare Peripheral Neuropathies
(NNERF) [41]. However, liver transplant is not
readily accessible to many patients. ATTReuNET
members reported an average wait of up to 1 year
in France, Spain, Italy, and Sweden, increasing to
2–3 years for patients in Germany, the Nether-
lands, Portugal, and Cyprus (liver transplant not
performed in Turkey).
Whereas liver transplant removes the main
source of mutated TTR [42–44], it does not pre-
vent progression of cardiac disease because the
wild-type TTR may continue to further expand
existing amyloid deposits in the heart [45
&&
,46].
Therefore, continued scrutiny of the cardiac sys-
tem is warranted, as some patients will develop
atrioventricular blocks or infiltrative cardio-
myopathy several years or decades later; a com-
bined heart and liver transplant may be
recommended in selected patients with non-
Val30Met mutations and cardiomyopathy
[47,48
&
,49–51]. However, ocular and central nerv-
ous system involvements often progress and/or
appear after liver transplant due to the local syn-
thesis of mutated TTR in retinal epithelium and
coroid plexus [52–54].r Health, Inc. All rights reserved.
rved. www.co-neurology.com S19
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First European consensus Adams et al.Tafamidis
Tafamidis is a first-in-class therapy that slows the
progression of TTR amyloidogenesis by stabilizing
the mutant TTR tetramer, thereby preventing its
dissociation into monomers and amyloidogenic
and toxic intermediates [55,56]. Tafamidis is cur-
rently indicated in Europe for the treatment of TTR
amyloidosis in adult patients with stage I sympto-
matic polyneuropathy to delay peripheral neuro-
logical impairment [57].
In an 18-month, double-blind, placebo-
controlled study of patients with early-onset
Val30Met TTR-FAP, tafamidis was associated with
a 52% lower reduction in neurological deterioration
(P¼0.027), a preservation of nerve function, and
TTR stabilization versus placebo [58
&&
]. However,
only numerical differences were found for the copri-
mary endpoints of neuropathy impairment [neuro-
pathy impairment score in the lower limb (NIS-LL)
responder rates of 45.3% tafamidis vs 29.5%
placebo; P¼0.068] and quality of life scores [58&&].
A 12-month, open-label extension study showed
that the reduced rates of neurological deterioration
associated with tafamidis were sustained over
30 months, with earlier initiation of tafamidis link-
ing to better patient outcomes (P¼0.0435) [59&].
The disease-slowing effects of tafamidis may be
dependent on the early initiation of treatment.
In an open-label study with Val30Met TTR-FAP
patients with late-onset and advanced disease
(NIS-LL score >10, mean age 56.4 years), NIS-LL
and disability scores showed disease progression
despite 12 months of treatment with tafamidis,
marked by a worsening of neuropathy stage in
20% and the onset of orthostatic hypotension in
22% of patients at follow-up [60
&
].
Tafamidis is not only effective in patients exhib-
iting the Val30Met mutation; it also has proven
efficacy, in terms of TTR stabilization, in non-Val30-
Met patients over 12 months [61]. Although tafa-
midis has demonstrated safe use in patients with
TTR-FAP, care should be exercised when prescribing
to those with existing digestive problems (e.g., diar-




Diflunisal is a nonsteroidal anti-inflammatory drug
(NSAID) that, similar to tafamidis, slows the rate of
amyloidogenesis by preventing the dissociation,
misfolding, and misassembly of the mutated TTR
tetramer [62,63]. Off-label use has been reported for
patients with stage I and II disease, although diflu-
nisal is not currently licensed for the treatment of
TTR-FAP.
Evidence for the clinical effectiveness of diflu-
nisal in TTR-FAP derives from a placebo-controlled, Copyright © 2016 Wolters Kluwe
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights resedouble-blind, 24-month study in 130 patients with
clinically detectable peripheral or autonomic neuro-
pathy [64
&
]. The deterioration in NIS scores was
significantly more pronounced in patients receiving
placebo compared with those taking diflunisal
(P¼0.001), and physical quality of life measures
showed significant improvement among diflu-
nisal-treated patients (P¼0.001). Notable during
this study was the high rate of attrition in the
placebo group, with 50% more placebo-treated
patients dropping out of this 2-year study as a result
of disease progression, advanced stage of the disease,
and varied mutations.
One retrospective analysis of off-label use of
diflunisal in patients with TTR-FAP reported treat-
ment discontinuation in 57% of patients because of
adverse events that were largely gastrointestinal [65].
Conclusions on the safety of diflunisal in TTR-FAP
will depend on further investigations on the impact
of known cardiovascular and renal side-effects
associated with the NSAID drug class [66,67].
Symptomatic management
The management of symptoms associated with sen-
sory-motor neuropathy and autonomic dysfunction
should be initiated immediately following diagnosis
and should be tailored to the individual patient [10].
Symptomatic treatment may include painkillers,
antidiarrhoeal drugs, treatment of symptomatic
orthostatic hypotension, diuretics for patients with
cardiac failure,prophylacticpacemaker implantation
for severe cardiac conduction disorders [32
&&
], or
vitrectomy/trabeculectomy for the treatment for
ocular amyloidosis or glaucoma, respectively [10].
Emerging therapies
A number of new treatments for TTR-FAP are
currently in phase II or III development. Posttran-
scriptional gene silencing is an approach that aims to
inhibit the hepatic production of mutant and non-
mutant TTR using small interfering RNAs [68
&&
] or
antisense oligonucleotides [6]. Two phase III trials
are ongoing, involving ALN-TTR02, an RNA interfer-
ence (NCT01960348) [69], and ISIS 420915, an anti-
sense oligonucleotide (NCT01737398) [70]. The
removal of amyloid deposits has also been demon-
strated in mouse models using a synergistic combi-
nation of doxycycline and tauroursodeoxycholic
acid (TUDCA) [71], with ongoing clinical trials
seeking to replicate these findings in patients
(NCT01855360, NCT01171859) [72,73]. Preliminary
data from the latter, a small phase II study, are prom-
ising, showing stabilization of neuropathy scores
over 12 months of treatment with no clinical pro-
gression of cardiac involvement [74]. Immunother-




Patient aged >50 years or
CI for LTa
Patient aged <50 years and






















FIGURE 1. Strategy for specific therapy in TTR-FAP. CI, contraindications; LT, liver transplantation; TTR-FAP, transthyretin
familial amyloid polyneuropathy. aCI for LT include: active and uncontrolled cancer; aged >50 years for males and
>70 years for females [39&&,77], except for Italy (aged >65 years); modified body mass index below 800 kg/m2g/L; some
non-Val30Met TTR mutations; cardiac insufficiency. bStage I: walking unaided outside. cStage II: walking with aid. dProtocol
clinical trial for antisense oligonucleotides, small interfering RNA, combination doxycycline–tauroursodeoxycholic acid; or
diflunisal off-label. Adapted from [1&].
Consensus for transthyretin amyloid neuropathythe specific amyloid protein by enhancing the clear-
ance of these deposits with monoclonal antibodies.
Currently, a number of antibodies [e.g., monoclonal
antibody NEOD001; the combination of a serum
amyloid P (SAP) depleter (GSK2315698) and an
anti-SAP antibody (GSK2398852)] are undergoing
testing in patients with various forms of amyloidosis
(NCT01707264, NCT01777243) [75,76].A comprehensive care strategy
ATTReuNETrecommends a multidisciplinary appro-
ach to the management of TTR-FAP including not
only the diagnosing physician, but also a neurol-
ogist and a cardiologist, and possibly an ophthal-
mologist, in the initial assessment and subsequent
reviews. Treatment strategies should also extend
beyond antiamyloid therapy (surgical or pharmaco-
therapeutic) to include symptomatic treatment, the
management of complications (e.g., cardiac failure, Copyright © 2016 Wolters Kluwer 
S22 www.co-neurology.comend-stage renal disease), and genetic counselling
(to be detailed in the next part of this supplement
[37]). Figure 1 presents a comprehensive treatment
algorithm for TTR-FAP, developed by the group.
Physicians should note that existing treatments
are most effective in patients with stage I TTR-
FAP, with limited data available on the efficacy in
more advanced stages, different genotypes, and late-
onset variants.
Ongoing monitoring is crucial and permits sys-
tematic tracking of TTR-FAP disease progression.
Figure 2 describes an algorithm for patient follow-
up during active treatment. Clinical and bio-
chemical assessment should take place no later than
3 months from treatment initiation, with a full,
multidisciplinary consultation at 6 and 12 months.
Patients should be assessed biannually or as required
at their TTR-FAP clinic, withmonitoringmaintained
throughout their lives. Ideally, the review should
involve a neurologist, a cardiologist, and an internalHealth, Inc. All rights reserved.























6 and 12 monthsa
Clinical examination
-   Functional neurological scores
    (e.g., walking ability, PND)
-   Autonomic (e.g., bladder/UTI,
    OH, erectile dysfunction)
-   Examination: sensory motor (NIS), OH





FIGURE 2. Algorithm for patient follow-up during treatment for TTR-FAP (compiled from clinical experience of ATTReuNET in
March 2014). AE, adverse event; ECG, electrocardiogram; mBMI, modified body mass index; NIS, Neurological Impairment
Scale; OH, orthostatic hypotension; PND, modified polyneuropathy disability score; TTR-FAP, transthyretin familial amyloid
polyneuropathy; UTI, urinary tract infection. aQuarterly basis for those with more advanced (stage II, III) disease unless
responding well to treatment.
First European consensus Adams et al.medicine specialist (depending on local practice) at
each visit. Regular follow-up with the multidiscipli-
nary team can help to diminish a patient’s anxiety
and aid the acceptance of the diagnosis, as well as
enable the detection of new manifestations of amy-
loid deposits and other disease symptoms. Patients
withmore advanced disease (stage II or III) should be
seen on a quarterly basis, whereas those who
respond well to treatment can be followed up less
regularly.CONCLUSION
TTR-FAP is a rare but life-threatening disease.
Given the limited window for treatment effective-
ness, an early and accurate diagnosis followed
by appropriate therapeutic intervention is critical.
The establishment of direct referral systems
through NRCs across Europe allows the pooling
of clinical resources and expertise to help reduce
misdiagnosis and delay to treatment. Increased
awareness of existing nonclassical TTR-FAP patient
groups (e.g., sporadic cases) will help to direct Copyright © 2016 Wolters Kluwe
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseand streamline the diagnostic process, enabling
early implementation of specific strategies and
better patient outcomes. The recent emergence
of alternatives to liver transplantation has greatly
enhanced the treatment options available to
patients with TTR-FAP.
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